Browsing by title
Now showing items 2925-2944 of 4786
-
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
(BMJ PUBLISHING GROUP, 2023-01-01)BACKGROUND: Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients ... -
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
(ASSOC DEVELOPPEMENT COMMUNICATION CANCEROLOGIQUE, 2021-11-01)Since the proof of concept of synthetic lethality between poly(ADP-ribose) polymerase inhibition and loss of BRCA1/2 homologous recombination (HR) function in preclinical models and early phase clinical trials, poly(ADP-ribose) ... -
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.
(ELSEVIER, 2024-03-01)The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as ... -
New target volume delineation and PTV strategies to further personalise radiotherapy.
(IOP PUBLISHING LTD, 2021-02-25)Target volume delineation uncertainty (DU) is arguably one of the largest geometric uncertainties in radiotherapy that are accounted for using planning target volume (PTV) margins. Geometrical uncertainties are typically ... -
New tricks for an old dog: Brf2-dependent RNA Polymerase III transcription in oxidative stress and cancer.
(TAYLOR & FRANCIS INC, 2018-01-01)Here, we discuss the role of Brf2, an RNA Polymerase III core transcription factor, as a master switch of the oxidative stress response. We highlight the interplay of Brf2 with the Nrf2/Keap1 pathway, as well as the role ... -
Next Generation Cancer Vaccines-Make It Personal!
(2018-08-09)Dramatic success in cancer immunotherapy has been achieved over the last decade with the introduction of checkpoint inhibitors, leading to response rates higher than with chemotherapy in certain cancer types. These responses ... -
Next generation circulating tumour DNA detection and subclonality analysis for gastrointestinal cancer therapy personalisation
(Institute of Cancer Research (University Of London), 2021-05-31)Background: Gastrointestinal cancers are associated with poor outcomes as many patients present with advanced disease. Intratumour heterogeneity (ITH) is a major barrier to predicting the evolution of cancers and successful ... -
Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC).
(FRONTIERS MEDIA SA, 2020-04-17)Background: Following chemo-radiotherapy (CRT) for human papilloma virus positive (HPV+) anal squamous cell carcinoma (ASCC), detection of residual/recurrent disease is challenging. Patients frequently undergo unnecessary ... -
The next wave of interactomics: Mapping the SLiM-based interactions of the intrinsically disordered proteome.
(CURRENT BIOLOGY LTD, 2023-06-01)Short linear motifs (SLiMs) are a unique and ubiquitous class of protein interaction modules that perform key regulatory functions and drive dynamic complex formation. For decades, interactions mediated by SLiMs have ... -
Next-Generation Sequencing and Image-Guided Tissue Sampling: A Primer for Interventional Radiologists.
(Elsevier BV, 2023-03-01)The discovery of increasing numbers of actionable molecular and gene targets for cancer treatment has driven the demand for tissue sampling for next-generation sequencing (NGS). Requirements for sequencing can be very ... -
Next-generation sequencing for the management of sarcomas with no known driver mutations.
(LIPPINCOTT WILLIAMS & WILKINS, 2021-07-01)PURPOSE OF REVIEW: Next-generation sequencing (NGS) has enabled fast, high-throughput nucleotide sequencing and has begun to be implemented into clinical practice for genomic-guided precision medicine in various cancer ... -
Night shift work and risk of breast cancer in women: the Generations Study cohort.
(NATURE PUBLISHING GROUP, 2019-07-16)BACKGROUND: It is plausible that night shift work could affect breast cancer risk, possibly by melatonin suppression or circadian clock disruption, but epidemiological evidence is inconclusive. METHODS: Using serial ... -
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
(CELL PRESS, 2024-03-19) -
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
(Elsevier BV, 2024-03-19)Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This multicenter, ... -
Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
(ELSEVIER SCIENCE BV, 2016-06-01)BACKGROUND: In active surveillance (AS) for prostate cancer there are few data on long-term outcomes associated with novel imaging markers. OBJECTIVE: To determine long-term outcomes with respect to the apparent diffusion ... -
Nipple sparing versus skin sparing mastectomy: a systematic review protocol.
(2016-05-20)Introduction Breast cancer has a lifetime incidence of one in eight women. Over the past three decades there has been a move towards breast conservation and a focus on aesthetic outcomes while maintaining oncological safety. ... -
Nipple-sparing mastectomy in women at high risk of developing breast cancer.
(AME PUBLISHING COMPANY, 2018-06-01)Nipple-sparing mastectomy is a valuable addition to the options available for women at high risk of developing breast cancer. In this review, we summarize current knowledge about the high-risk genes, BRCA1, BRCA2 and TP53 ... -
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.
(AMER ASSOC CANCER RESEARCH, 2021-10-15)PURPOSE: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. PATIENTS AND METHODS: BRAVO was a randomized, open-label phase III trial. Eligible patients had ... -
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
(American Society of Clinical Oncology (ASCO), 2023-02-13)PURPOSE: Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated ... -
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
<h4>Background</h4>First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously ...